These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33050168)

  • 1. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
    Bose P; Masarova L; Verstovsek S
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruxolitinib.
    Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and management of myelofibrosis in the era of JAK inhibitors.
    Keohane C; Radia DH; Harrison CN
    Biologics; 2013; 7():189-98. PubMed ID: 23990704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Myeloproliferative neoplasms: recent progresses in therapy].
    Kamiunten A; Shide K; Shimoda K
    Rinsho Ketsueki; 2018; 59(6):741-746. PubMed ID: 29973454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
    Nazha A; Gerds AT
    Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):277-86. PubMed ID: 25696867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.
    Lee SS; Verstovsek S; Pemmaraju N
    J Immunother Precis Oncol; 2021 Aug; 4(3):117-128. PubMed ID: 35663101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Soret J; Kiladjian JJ
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [What's new in myeloproliferative neoplasia?].
    Schmidt S; Wolf D
    Dtsch Med Wochenschr; 2022 Mar; 147(6):306-311. PubMed ID: 35291035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
    Bose P; Verstovsek S
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib for the Treatment of Essential Thrombocythemia.
    Gunawan A; Harrington P; Garcia-Curto N; McLornan D; Radia D; Harrison C
    Hemasphere; 2018 Aug; 2(4):e56. PubMed ID: 31723782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA; Mesa RA; Hoffman R; Shammo JM
    Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
    Nazha A; Khoury JD; Verstovsek S; Daver N
    Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease modifying agents of myeloproliferative neoplasms: a review.
    Lee SE
    Blood Res; 2021 Apr; 56(S1):S26-S33. PubMed ID: 33935032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State-of-the-Art Review on Myelofibrosis Therapies.
    Wang F; Qiu T; Wang H; Yang Q
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.
    Bose P
    Expert Opin Orphan Drugs; 2019; 7(10):415-425. PubMed ID: 33094033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms.
    Pozdnyakova O; Hasserjian RP; Verstovsek S; Orazi A
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):253-61. PubMed ID: 25515354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates in the management of polycythemia vera and essential thrombocythemia.
    Bose P; Verstovsek S
    Ther Adv Hematol; 2019; 10():2040620719870052. PubMed ID: 31516686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.